|Bid||157.15 x 20000|
|Ask||159.75 x 20000|
|Day's range||157.10 - 157.10|
|52-week range||136.05 - 201.95|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||38.04|
|Forward dividend & yield||2.21 (1.43%)|
|Ex-dividend date||11 Sept 2023|
|1y target est||N/A|
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) granted approval for ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18 years and older.
This Sunday, 26 November, marks Iron Deficiency Day, a day dedicated to raising awareness about the importance of diagnosing and treating iron deficiency and iron deficiency anemia. Supported by an alliance of international patient organizations and health advocacy groups, CSL Vifor takes a leading role annually to educate people about the importance of iron for the body and what can happen if iron levels are not properly managed. It encourages people to become better informed and to seek medica
Global biotechnology leader CSL (ASX: CSL) and uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the companies have received the 2023 Prix Galien USA Award in the category of Best Product for Rare/Orphan Diseases for HEMGENIX® (etranacogene dezaparvovec-drlb).